Fuho Capital
VC Fund
Haidian, China
Fuho Capital is an equity investment fund management company.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Fuho Capital invests in
Stages Fuho Capital invests in
Countries Fuho Capital invests in
Round sizes
Round size
- Angel
- $425k–$2.8M
- Series A
- $709k–$15M
- Series B
- $2.8M–$44M
Investment Focus
Industry
- Health Care 11 (34%)
- Biotechnology 10 (31%)
- Medical 8 (25%)
- Pharmaceutical 7 (22%)
- Biopharma 4 (13%)
Stage
- Series A 11 (34%)
- Angel 8 (25%)
- Series B 5 (16%)
- Seed 3 (9%)
- Series C 1 (3%)
Country
- China 23 (72%)
- Switzerland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Novamab
|
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $43.9M / Series B / Apr 24, 2026 | |
Hexaell Biotech
|
Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from ChineseAcademy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China. | $14.6M / Series B / Apr 24, 2026 | |
Leman Biotech
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $28.8M / Series A / Jan 26, 2026 | |
Cascade
|
Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation. | $42.4M / Series B / Nov 28, 2025 | |
|
Sheng Sheng Biology
|
Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services. | Series A / Nov 21, 2024 | |
|
Leman Biotech
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | Series A / Nov 12, 2024 | |
|
Novamab
|
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $24.4M / Series B / Jul 03, 2024 | |
|
Leman Biotech
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $7M / Seed / Jun 18, 2024 | |
Leming Pharmaceuticals
|
Le Ming Pharmaceuticals is a pharmaceutical enterprise focusing on R&D, production and sales of innovative pharmaceutical preparation. | $13.8M / Venture - Series Unknown / Jun 07, 2024 | |
Hengsai Biological
|
Hengsai Bio is a tumor immunotherapy developer that engages in R&D and industrialisation of a new generation dendritic cell tumor vaccines. | $14M / Series A / Nov 27, 2023 | |
| See all 32 investments → | |||
Co-Investors
Gaorong Capital
3 deals together
XtalPi
3 deals together
CSC Group
2 deals together
Heaven-Sent Capital Management
2 deals together
Qiming Venture Partners
2 deals together
Shangshi Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fuho Capital invest in?
Fuho Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Angel stage. Most of the 32 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fuho Capital's check size?
Fuho Capital typically joins rounds of $425k–$2.8M at Angel, $709k–$15M at Series A and $2.8M–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fuho Capital participates in.
When did Fuho Capital last invest?
The most recent investment recorded for Fuho Capital closed in Apr 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
